Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2026-02-12 Regulatory Filings
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Preliminary Interim Results From Dog Study
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from Genflow Biosciences Plc dated 12 February 2026, reporting positive preliminary interim results from a clinical trial (SLAB) of their SIRT6 gene therapy in aged dogs. It provides detailed information about the trial design, interim results, ongoing analyses, and commercial implications. The document is not a full financial report but a clinical trial update and company progress announcement. It is not an earnings release, annual report, or interim financial report. It is a regulatory announcement providing material information to the market about clinical trial progress and company developments. The document length is 9457 characters, which is substantive but does not contain financial statements or detailed financial analysis. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like earnings, capital updates, or management changes.
2026-02-12 English
Notice of GM
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from Genflow Biosciences Plc regarding a Notice of General Meeting to seek shareholder approval for a potential equity raise through issuing new shares. It discusses the purpose of the equity raise, the terms to be approved, and the details of the upcoming General Meeting. There is no actual financial data or report content such as financial statements or management discussion. The document is an announcement about a shareholder meeting and a potential capital raise, not the actual capital raise or financial report itself. It is not a full financial report, earnings release, or management report. The document fits best into the category of Capital/Financing Update (CAP) because it provides an update on potential fundraising activities and capital structure changes, specifically the planned equity raise and shareholder approval process.
2026-02-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Genflow Biosciences PLC. It details a change in voting rights held by a shareholder (Jonathan Mark Swann), specifically crossing a threshold. This matches the definition of a Major Shareholding Notification (MRQ).
2026-01-30 English
Administrative Approval of Grant & 2026 Priorities
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (RNS) from Genflow Biosciences PLC regarding the administrative approval of funding support and an update on 2026 development priorities. It is a corporate news release detailing operational and financial updates rather than a formal financial report, proxy statement, or audit. As it provides specific updates on company financing and strategic development, it falls under the 'Capital/Financing Update' category.
2026-01-28 English
Directorate change
Board/Management Information Classification · 100% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). The core content of the text is the formal announcement of the appointment of a new Independent Non-Executive Chairman to the Board of Directors of Genflow Biosciences PLC. This falls directly under the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-01-19 English
Review of 2025
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Genflow Biosciences PLC titled 'A Review of an Exciting 2025'. It provides a narrative summary of the company's operational progress, clinical trial updates, and strategic outlook for 2026. It does not contain full financial statements, nor is it a formal quarterly or annual report. As it is a corporate update regarding business activities and strategy rather than a specific financial filing, it falls under the general regulatory announcement category.
2026-01-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.